Pavle Repovic
Pavle Repovic, MD, PhD

Pavle Repovic, MD, PhD

Pavle Repovic, MD, PhD

Multiple Sclerosis, Neurology

Clinical Interests / Special Procedures Performed

Autoimmune Disorders, Clinical Research & Educ., Clinical Trials, Double Vision, Immunology, Limb Numbness, Multiple Sclerosis, Multiple Sclerosis Clinics at SNI, Neuroimmunology, Swedish Neuroscience Institute

  • Accepting Children: Unknown
  • Accepting New Patients: Yes
  • Accepting Medicare: Yes
  • Accepting Medicaid/DSHS: Yes
Payment Methods Accepted:

Bill insurance, Cash, Check, MasterCard, Payment plan, Sliding fee scale, Visa

Insurance Accepted:

most plans, except GAU

Additional Information:

Dr. Repovic was voted "Top Doctors" in Seattle Metropolitan Magazine (2011, 2012, 2013)

Physicians, nurses and physician assistants in King, Kitsap and Snohomish counties nominated colleagues they would choose to treat themselves and their loved ones.

News Release

Philosophy of Care

Offering my patients the guidance and support to effectively manage their condition and lead a fuller life

Personal Interests

foreign languages, cultures and cuisine; tango; nature

Medical School

University of Alabama School of Medicine


Cornell - New York Presbyterian Hospital


Mount Sinai Hospital, New York

Board Certifications

American Board of Psychiatry and Neurology


English, Serbo-Croatian, Spanish

Professional Associations:

Diplomate, American Board of Psychiatry and Neurology; Member, American Academy of Neurology


Sylvia Lawry Fellowship (2008-2010, National MS Society); Young Investigator Fellowship (2002, International Society for Neurochemistry)

Additional Information:

Dr. Repovic was voted "Top Doctors" in Seattle Metropolitan Magazine (2011, 2012, 2013)

Physicians, nurses and physician assistants in King, Kitsap and Snohomish counties nominated colleagues they would choose to treat themselves and their loved ones.

News Release

Peer-reviewed original contributions:
1) Repovic P, Lublin F (2010) Treatment of multiple sclerosis exacerbations. Neurol Clinics North America, in press.
2) Repovic P, Fears C, Gladson CL, Benveniste EN (2003) Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 22(50), 8117-24.
3) Repovic P, Mi K, Benveniste EN (2003) Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha and bacterial LPS. Glia 42(4), 433-46.
4) Repovic P, Benveniste EN (2002) Prostaglandin E2 is a novel inducer of Oncostatin M expression in macrophages and microglia. J Neurosci 22(13), 5334-43.
5) Van Wagoner NJ, Choi C, Repovic P, Benveniste EN (2000) Oncostatin M regulation of interleukin-6 expression in astrocytes: biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38. J Neurochem 75(2), 563-75.
6) Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN (1999) IL-6 production by astrocytes:autocrine regulation by IL-6 and soluble IL-6 receptor. J Neurosci 19(13), 5236-44.
7) Waddel TG, Repovic P, Melendez-Hevia E, Heinrich R, Montero F (1997) Optimisation of glycolysis: a new look at the efficiency of energy coupling; Biochem Educ 25(4), 204-205.

Books and Chapters:
• Repovic P. Molecular Neurobiology and Neurotrauma chapters in the 2006 Psychiatry In-Review Study Guide, ed. S. J. Ferrando, ETAS. New York, 2006

HPV vaccination and risk of MS

As long as the cause of multiple sclerosis (MS) remains unknown, it will be tempting – for patients and doctors alike – to search for an explanation among events that occurred before the diagnosis. This approach, known from antiquity as post hoc, ergo propter hoc (after the fact, therefore because of the fact), though sometimes successful, can also be misleading. History of science in general, and multiple sclerosis in particular, is rife with such fallacies. It is important to remember then, that this approach is best thought of as “brainstorming”, generating potential leads, but (almost) never the definitive proof.

Gilenya fails in primary progressive multiple sclerosis trial

We recently found out that Gilenya (fingolimod), an oral treatment for relapsing multiple sclerosis (MS), did not slow down disability progression in a phase III trial among primary progressive MS (PPMS) patients. The trial, called INFORMS, was the largest to date in PPMS, involving 970 patients in North America, Europe, and Australia. Patients were assigned to placebo or Gilenya for 3 years, and the primary outcome was a composite of walking, arm function and overall disability measures. Unfortunately, the progression rates in Gilenya and placebo groups were not statistically different. A full report of the trial will be presented at one of the upcoming neurology meetings, possibly in April 2015.

A (Slightly) New Medication for Multiple Sclerosis Comes Out in November

Interferons have been used for the treatment of multiple sclerosis (MS) since 1993. The existing line-up of interferons for MS (Avonex, Betaseron, Extavia and Rebif) will soon be joined by Plegridy, approved by the US Food and Drug Administration in August 2014. Plegridy will become commercially available in November 2014.

Plegridy is a pegylated form of interferon beta. Pegylation is a process, used by several other non-MS medications, whereby a long string of polyethylene glycol molecules is attached to the interferon beta molecule, to extend its half-life by reducing clearance via kidneys or other elimination pathways in the body. This modification allows less frequent dosing of Plegridy – once every two weeks – although it is still administered as an injection under the skin.

In the ADVANCE trial, Plegridy was ..

FDA declines approval of Lemtrada for the treatment of MS

On December 30, 2013, the US Food and Drug Administration declined to approve the use of alemtuzumab (Lemtrada) for the treatment of multiple sclerosis. The FDA stated that the manufacturer of Lemtrada “has not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects.” This was a surprising decision to some, as only a month earlier an advisory panel of experts convened by the FDA, while raising some objections, voted to have this medicine approved. The manufacturer of Lemtrada, Genzyme, a Sanofi company, intends to appeal this decision.
In response, a number of MS organizations and experts have voiced their concerns that with this step, MS patients are left without a potential choice in therapy. This decision is particularly difficult for ...

2013 World Atlas of MS published

The 2013 World Atlas of MS has been published by MS International Foundation and is available here. The key findings are:

  1. The estimated number of people with MS has increased from 2.1 million in 2008 to 2.3 million in 2013
  2. The 2:1 ratio of women to men with MS has not changed significantly since 2008
  3. Substantial global inequalities remain in terms of access to treatment and medical care

Is someone with multiple sclerosis an MSer?

A survey from the United Kingdom published in the Journal of MS and Related Disorders polled 396 people with multiple sclerosis (MS) about how they would like to be referred to in conversation. The winning term ("MSer") was supported by 43% of the respondents, while "person with MS" received 34% votes. When a United States-based blog reported on the story, 2 out of 3 respondents disagreed.

What do you think? Comment below with your preference and why.


(Ed. note: You can comment anonymously - feel free to use your initials if you are more comfortable sharing that way.)

MS Research Roundup: Cannabinoids and new trials for progressive MS

A couple recent announcements may be of interest to people living with multiple sclerosis. Read the articles below and click through the links for more information about the individual studies.

Trial shows no benefit of cannabinoid in slowing multiple sclerosis progression

A UK trial of dronabinol (delta-9-THC) in 498 patients did not slow the progression of multiple sclerosis (MS) compared to placebo. Critics will point out that this is only one of many cannabinoids found in marijuana; and that the placebo arm did better than expected (thus limiting the ability to detect the effects of the drug). Nonetheless, the result is the strongest argument yet against the neuroprotective effects of THC in MS population.

New trials in progressive MS are coming

Later this year, two trials will ...

Results 1-7 of 10


Multiple Sclerosis Center
1600 East Jefferson
A Level
Seattle, WA 98122
Phone: 206-320-2200
Fax: 206-320-2560
Map & Directions
Neuroscience Institute Administrative Office
550 17th Avenue
Suite 500
Seattle, WA 98122
Phone: 206-320-2800
Fax: 206-320-2827
8 a.m. - 4:30 p.m.
Map & Directions

Physicians: Is this your profile? Click here for info


This provider is affiliated with: